Profile data is unavailable for this security.
About the company
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
- Revenue in USD (TTM)52.79bn
- Net income in USD22.98bn
- Incorporated1996
- Employees108.00k
- LocationNovartis AGLichtstrasse 35BASEL 4056SwitzerlandCHE
- Phone+41 613241111
- Fax+41 613247826
- Websitehttps://www.novartis.com/
More ▼
Mergers & acquisitions
| Acquired company | NOVN:SWX since announced | Transaction value |
|---|---|---|
| Gyroscope Therapeutics Holdings PLC(WAS 4L1215) | 4.91% | 1.50bn |
| Alnylam Pharmaceuticals Inc | 9.24% | -- |
| Arctos Medical AG | 7.84% | -- |
Data delayed at least 15 minutes, as of Aug 09 2022 16:36 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | 26.60bn | 1.46bn | 45.85bn | 47.35k | 31.05 | 0.9607 | 7.78 | 1.72 | 126.39 | 126.39 | 2,296.99 | 4,085.66 | 0.2688 | 1.36 | 4.52 | 75,862,610.00 | 1.48 | 1.86 | 1.73 | 2.24 | 67.75 | 68.85 | 5.50 | 6.98 | 0.7485 | 3.53 | 0.4215 | 123.94 | 11.61 | 15.56 | -38.81 | 14.89 | 10.68 | 0.00 |
| Chugai Pharmaceutical Co Ltd | 8.93bn | 2.88bn | 46.44bn | 7.66k | 15.79 | 4.70 | -- | 5.20 | 236.46 | 236.46 | 732.88 | 794.74 | 0.8311 | 1.96 | 4.71 | 157,319,400.00 | 26.82 | 16.07 | 32.40 | 19.41 | 66.08 | 61.17 | 32.26 | 23.47 | 3.08 | -- | 0.00 | 44.38 | 27.04 | 15.25 | 41.10 | 41.41 | 14.88 | 34.40 |
| Bayer AG | 49.31bn | 4.32bn | 53.04bn | 101.91k | 12.27 | 1.37 | 6.19 | 1.08 | 4.31 | 4.31 | 49.22 | 38.70 | 0.398 | 1.71 | 3.47 | 485,331.80 | 3.51 | -1.37 | 4.71 | -1.77 | 61.89 | 59.99 | 8.82 | -3.73 | 0.8376 | 5.45 | 0.5388 | -- | 6.48 | 4.76 | 106.42 | -23.20 | 0.2547 | -5.52 |
| Novartis AG (ADR) | 52.79bn | 22.98bn | 205.78bn | 108.00k | 8.42 | 2.98 | 7.09 | 3.90 | 10.21 | 10.21 | 23.57 | 28.83 | 0.4276 | 2.19 | 6.19 | 506,005.40 | 18.61 | 9.08 | 24.25 | 11.56 | 70.92 | 70.62 | 43.53 | 24.73 | 1.13 | -- | 0.33 | 58.80 | 5.97 | 1.38 | 197.58 | 29.05 | 0.6311 | 3.31 |
| Roche Holding AG | 67.41bn | 15.35bn | 275.91bn | 100.92k | 17.86 | 10.04 | 13.21 | 4.09 | 17.68 | 17.68 | 77.20 | 31.46 | 0.7374 | 2.39 | 5.73 | 637,960.80 | 18.19 | 15.62 | 27.70 | 23.77 | 69.18 | 71.04 | 24.66 | 21.82 | 0.8037 | 20.32 | 0.4895 | 62.04 | 7.68 | 4.42 | -2.55 | 7.78 | -1.99 | 2.55 |
Data as of Aug 09 2022. Currency figures normalised to Novartis AG's reporting currency: US Dollar USD
4.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dodge & Coxas of 31 Mar 2022 | 27.84m | 1.16% |
| PRIMECAP Management Co.as of 31 Mar 2022 | 17.78m | 0.74% |
| Loomis, Sayles & Co. LPas of 30 Jun 2022 | 15.49m | 0.64% |
| Fisher Asset Management LLCas of 31 Mar 2022 | 10.87m | 0.45% |
| Franklin Mutual Advisers LLCas of 31 Mar 2022 | 7.14m | 0.30% |
| Managed Account Advisors LLCas of 31 Mar 2022 | 6.27m | 0.26% |
| Boston Partners Global Investors, Inc.as of 31 Mar 2022 | 4.61m | 0.19% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2022 | 4.40m | 0.18% |
| Dimensional Fund Advisors LPas of 31 Mar 2022 | 4.36m | 0.18% |
| Wellington Management Co. LLPas of 31 Mar 2022 | 4.13m | 0.17% |
More ▼
Data from 31 Mar 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
